2025-01-12 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO):**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases.

The cumulative return of VRTX is 132.78%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 112.20%.  The difference is 20.6%, placing it at the 54.2nd percentile of its historical performance range relative to the S&P 500 (based on a minimum difference of -65.6% and a maximum of 93.5%).  This suggests a relatively strong outperformance compared to its historical performance against the S&P 500.

The provided Alpha and Beta analysis shows consistently positive Alpha (outperformance relative to the market), although Beta (market sensitivity) is relatively stable around 0.1, indicating lower sensitivity to market fluctuations than the broader market.  However, note that the CAGR fluctuates significantly year-to-year, highlighting the inherent volatility in biotech investments.


**2. Recent Price Movement:**

* **Closing Price:** $409.56
* **5-Day Moving Average:** $407.92
* **20-Day Moving Average:** $422.76
* **60-Day Moving Average:** $457.54

The stock price is currently below its 5, 20, and 60-day moving averages, suggesting a potential downward trend in the short-to-medium term.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 31.17 – This indicates the stock is in oversold territory, potentially suggesting a bounce is possible.
* **PPO (Price Oscillator):** 0.1961 – A positive value suggests a bullish momentum, although it's relatively low.
* **20-Day Relative Divergence:** +2.3 – This suggests a short-term upward trend.
* **Expected Return:** 27.4% – This represents a substantial potential outperformance over the S&P 500 over the long term (2+ years) assuming continued strong performance.  However, this is just an estimate and should not be taken as guaranteed.
* **Current Price Context:**  The current price of $409.56, being below the moving averages, does not suggest a recent sharp upward or downward movement.  It's a relatively moderate decline from recent highs.


**4. Recent Earnings Analysis:**

The earnings data is inconsistent and requires further investigation to determine the trend.  There's a significant negative EPS in August 2024 (-13.92), which drastically skews the overall picture. Further analysis is needed to understand the reasons behind this outlier.  Revenue shows a generally upward trend, though not consistently.


| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-11-05 | 4.05   | $2.77B      |
| 2024-08-02 | -13.92 | $2.65B      |
| 2024-05-07 | 4.26   | $2.69B      |
| 2023-11-07 | 4.01   | $2.48B      |
| 2024-11-05 | 4.01   | $2.48B      | *(Duplicate entry, likely a data error)*


**5. Financial Information:**

The financial information presents a mixed picture.  Profit margins remain consistently high (85-87%), suggesting strong operational efficiency.  However, Return on Equity (ROE) shows significant volatility, including a large negative value in Q2 2024 (-24.32%), indicating potential concerns about capital utilization. Further investigation into the cause of this negative ROE is crucial. Revenue shows a generally increasing trend.


| Quarter    | Revenue | Profit Margin | Equity   | ROE     |
|------------|----------|---------------|----------|---------|
| 2024-09-30 | $2.77B  | 85.84%        | $15.63B | 6.69%   |
| 2024-06-30 | $2.65B  | 85.94%        | $14.77B | -24.32% |
| 2024-03-31 | $2.69B  | 87.27%        | $18.55B | 5.93%   |
| 2023-12-31 | $2.52B  | 85.38%        | $17.58B | 5.51%   |
| 2023-09-30 | $2.48B  | 87.17%        | $16.51B | 6.27%   |


**7. Overall Summary:**

VRTX has historically outperformed the S&P 500, showing strong long-term growth potential. However, recent price action suggests a potential short-term correction. The high profit margins are positive, but the volatile ROE and the inconsistent earnings data warrant further due diligence. The oversold RSI suggests a potential bounce, but the low PPO indicates limited momentum.  A thorough examination of the reasons behind the negative ROE and the outlier in the earnings data is essential before making any investment decisions. The projected long-term return is promising, but the risk associated with biotech investments should be considered.  Investors should carefully assess the company's pipeline, regulatory approvals, and competitive landscape before making any decisions.
